Abstract:Background and aims: Peroxisome proliferator-activated receptor alpha (PPARa) regulates expression of multiple genes involving lipid metabolism, bile acids (BA) homeostasis, and shows protective effects against inflammation and apoptosis.Progressive diseases such as primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) result in intrahepatic retention of toxic BA that may lead to liver dysfunction and failure.Small non-coding RNA molecules (miRNAs) regulate gene expression, and miR-155 was associated with silencing of PPARa.Since PPARa activation decreases inflammation and fibrosis we evaluated PPARa and miR-155 expressions in cholestatic livers.We have also analyzed the regulatory effect of miR-155 on PPARa expression in vitro.Method: Liver samples were taken from biopsies at early stages (F1-F2) of PBC (n = 12) or from explanted livers in patients with cirrhotic PBC (n = 11) and PSC (n = 17).The functional role of miR-155 was characterized in vitro in hepatocytes (HepG2) and primary cholangiocytes (NHC) where overexpression of miR-155 was induced by mirVana miRNA Mimic.miR-155 expression levels were evaluated after treatment with lipopolysaccharide (LPS), glycodeoxycholic acid (GCDCA), lithocholic acid (LCA) or ursodeoxycholic acid (UDCA).Results: When compared to controls hepatic PPARa mRNA and protein levels were reduced in cirrhotic PBC (both 50% reduction, P = 0.01), but not in PSC livers.In PBC livers this phenomenon was accompanied with induction of miR-155 (3.7-fold increase, P = 0.004 vs. control).Experimental overexpression of miR-155 in HepG2 led to the inhibition of PPARa (50% reduction, P = 0.02).LPS stimulated miR-155 expression in HepG2 (over 40-fold increase, p = 0.009), whereas the treatment with GCDCA or LCA enhanced the expression of miR-155 in NHC (2-fold p < 0.05, or 2.4 fold p < 0.05, respectively).UDCA suppressed the basal expression of miR-155 in NHC (20% reduction, p = 0.02 vs. control) as well as the LPS-induced miR-155 in HepG2 ( p = 0.009 vs LPS). Conclusion:We showed that PPARa is substantially reduced in PBC livers, and the observed concomitant overexpression of miR-155 induced either by inflammation or bile acids may be accountable for this suppression.Inhibition of miR-155 may be a potential novel therapeutic target in PBC.

Elevated Hepatic MDR3/ABCB4 is Directly Mediated by MiR-378a-5p in Human Obstructive Cholestasis.

Mir-301A-3p Promotes Hepatic Stellate Cells Activation and Liver Fibrogenesis Via Regulating PTEN/PDGFR-β.

MiR-103-3p Promotes Hepatic Steatosis to Aggravate Nonalcoholic Fatty Liver Disease by Targeting of ACOX1

Elevated Hepatic Multidrug Resistance-Associated Protein 3/Atp-Binding Cassette Subfamily C 3 Expression in Human Obstructive Cholestasis is Mediated Through Tumor Necrosis Factor Alpha and C-Jun NH2-terminal Kinase/stress-Activated Protein Kinase-Signaling Pathway.

Hepatic Overexpression of Mir-200B-3p Protects Hepatocytes in Patients with Obstructive Cholestasis

Correlation of transcriptional factors NR5A2 and SP1,bile acids transporter MRP3 with liver injury in human obstructive cholestasis

Changes of Organic Anion Transporter MRP4 and Related Nuclear Receptors in Human Obstructive Cholestasis

miR-199a-5p inhibits the expression of ABCB11 in obstructive cholestasis

TNFα Induces Multidrug Resistance-Associated Protein 4 Expression through p38-E2F1-Nrf2 Signaling in Obstructive Cholestasis

MiR-542-3p controls hepatic stellate cell activation and fibrosis via targeting BMP-7.

Nuclear Receptors RXRα:RARα Are Repressors for Human MRP3 Expression

Cholangiocytes-Specific Deletion of Sphingosine-1-phospholipid Receptor 1 Attenuate Cholestasis Induced Liver Injury and Fibrosis

The Function of Multidrug Resistance-associated Protein 3 in the Transport of Bile Acids under Normal Physiological and Lithocholic Acid-induced Cholestasis Conditions.

MicroRNA-376b-3p ameliorates nonalcoholic fatty liver disease by targeting FGFR1 and regulating lipid oxidation in hepatocytes

Changes of MRP2, RXRα and RARα expression in liver tissues of patients with obstructive cholestasis

Transcriptional Repression of CYP3A4 by Increased Mir-200A-3p and Mir-150-5p Promotes Steatosis in Vitro

Uncovering key molecules and immune landscape in cholestatic liver injury: implications for pathogenesis and drug therapy

Identification of a Potential Mirna-Mrna Regulatory Network Associated with the Pathogenesis of Cholestatic Liver Diseases

Canalicular membrane MRP2/ABCC2 internalization is determined by Ezrin Thr567 phosphorylation in human obstructive cholestasis

Regulation of MRP4 Expression by Circhipk3 Via Sponging Mir-124-3p/mir-4524-5p in Hepatocellular Carcinoma.

Long noncoding RNA MEG3 induces cholestatic liver injury by interaction with PTBP1 to facilitate shp mRNA decay